Stifel starts Dianthus at buy, cites market potential of lead drug [Seeking Alpha]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Seeking Alpha
Stifel said that it has modeled the drug achieving $2.7B in gross and $1.2B in risk-adjusted sales, “which could be conservative,” if the drug is approved for MG, CIDP and MMN. It noted that a Phase 2 study of the drug for MG is expected to begin this month, with data anticipated in 2H 2025. A Phase 2 study of the drug for MMN is slated to start in Q2, with a Phase 2 for CIPD expected to start in 2H 2024. Stifel noted that the company has around $389M in cash, with should be able to fund operations into 2H 2027. The investment firm set its price target for the stock at $44. Dianthus merged with Magenta Therapeutics last year. Recommended For You Recommended For You About DNTH Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $33.00 to $38.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsGlobeNewswire
- Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceGlobeNewswire
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
DNTH
Earnings
- 3/21/24 - Beat
DNTH
Sec Filings
- 5/9/24 - Form 424B3
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- DNTH's page on the SEC website